Please login to the form below

Not currently logged in
Email:
Password:

opioid abuse

This page shows the latest opioid abuse news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Despite finding that the “results demonstrate that Aximris XR would be an effective ER opioid analgesic with important improvements in abuse deterrence for the IV route”, the FDA had concerns that ... abuse. A number of pharma companies in the US

Latest news

  • Nektar’s opioid analgesic slammed with FDA panel rejection Nektar’s opioid analgesic slammed with FDA panel rejection

    Panelists unanimously rejected use of the chronic back pain drug. Nektar Therapeutics has been hit with a unanimous FDA panel rejection of its opioid painkiller, over concerns of drug abuse and ... High levels of euphoric side-effects from opioid

  • Teva names new CFO and bulks up its opioid liability fund Teva names new CFO and bulks up its opioid liability fund

    that over-marketing of opioid drugs was a key factor in the epidemic of opioid abuse, overdoses and death that has swept the country over the last few years. ... Under that settlement, Teva would pay $250m in cash over ten years and donate $23bn-worth of

  • Litigation concerns threaten to overshadow solid quarter at J&J Litigation concerns threaten to overshadow solid quarter at J&J

    Quite a lot of time on J&J’s conference call was however spent updating analysts on the litigation the company is facing on opioid medicines, talc, and antipsychotic drug Risperdal ... In August, J&J was ordered to pay Oklahoma $572m in  penalties

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Almost forgotten among the interest in Nektar’s immuno-oncology pipeline – which also includes three other candidates in clinical trials – is NKTR-181, a first-in-class, abuse-deterrent opioid analgesic ... The drug promises to deliver pain relief

  • AcelRX’s potent opioid tablets set to win FDA backing for pain relief AcelRX’s potent opioid tablets set to win FDA backing for pain relief

    Opioid abuse has reached epidemic proportions in the US, and the FDA has played its part in refusing approval to treatments that could be abused, while promoting treatments which are ... If given the final OK, the company notes that the drug would be the

More from news
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • "Legal highs" ruling leaves illegal labs laughing

    So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin.  . ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse.  .

  • How digital content is helping physicians curb the opioid abuse epidemic

    On the other hand are the prescribers who are driven to help their patients but finding that their pain management protocols are now complicated by what the national opioid abuse epidemic ... The pain management topic found under most specialties at

  • Aptus Health Aptus Health

    How digital content is helping physicians curb the opioid abuse epidemic.

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics